News & Events

News

All categories

Earnings

Press Release

All years

2021

2020

2019

2018

2017

2016

2015

2014

Affimed Announces R&D Strategy to Focus on Innate Immunity Portfolio; Reports First Quarter 2019 Financial Results and Operational Progress

May 22, 2019

Affimed Announces First Quarter 2019 Financial Results and Corporate Update Conference Call on May 22, 2019

May 16, 2019

Affimed Provides Regulatory Update on AFM11 Clinical Program

April 17, 2019

Affimed Highlights AFM24 Innate Cell Engager Novel Mechanism of Action and Potential for the Treatment of EGFR-expressing Solid Tumors at the American Association for Cancer Research (AACR) 2019 Annual Meeting

April 1, 2019

Affimed Reports 2018 Financial Results and Operational Progress

March 27, 2019

Affimed Announces Full Year 2018 Financial Results Conference Call on March 27, 2019

March 20, 2019

Affimed Announces Milestone Payment from Genentech and ROCK® Platform Presentation at Innate Killer Summit 2019, Further Highlighting Leadership in Innate Immunity

March 19, 2019

Affimed to Present Data on AFM13 and AFM24 at AACR Annual Meeting 2019

February 27, 2019

Affimed to Present at Upcoming Investor Conferences

February 21, 2019

Affimed to Present at the 37th Annual J.P. Morgan Healthcare Conference

January 4, 2019

Events

All

Scientific

Investors

23Mar

Innate Killer Summit

March 23 - 25, 2021 (virtual)

Webcasts
More events